Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
Enzomenib might be the most promising agent so far, on a cross-trial basis.
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
In first-line NSCLC the drug beats chemo, and not Keytruda.
